We explored the associations between lipoprotein-associated phospholipase A2 (Lp-PLA2) level and carotid atherosclerosis with all phenotypes and cardiovascular disease (CVD) events in Chinese older adults. A total of 1257 adults aged 55 years who were free of CVD were enrolled in this cohort study. Lipoprotein-associated phospholipase A2 level was evaluated in 3 categories: Lp-PLA2 < 175, 175 Lp-PLA2 < 223, and Lp-PLA2 223 ng/mL. The highest level of Lp-PLA2 was independently associated with common carotid artery intima-media thickening (1.0 mm; odds ratio [OR]: 1.60, 95% confidence interval [CI]: 1.14-2.26) and carotid plaque (OR: 1.42, 95% CI: 1.01-1.99) in individuals without carotid artery stenosis. At the end of the 5-year follow-up, after adjustment for CVD risk factors and carotid atherosclerosis status, Lp-PLA2 had remained an independent predictor for myocardial infarction (MI; hazard ratio [HR]: 1.90, 95% CI: 1.02-3.55) and CVD death (HR: 1.78, 95% CI: 1.02-3.13). However, no association was found with stroke. Therefore, elevated Lp-PLA2 level in the older adults studied was associated with an increased risk of carotid atherosclerosis and MI and CVD mortality. Lipoprotein-associated phospholipase A2 assessment might be used for MI and CVD death risk prediction.
Introduction
Cardiovascular disease (CVD), one of the leading causes of death in both men and women, has become a major challenge to public health in China where it has begun to appear at a younger age. 1 According to the report from the National Center for Cardiovascular Disease of China in 2012, over 290 million Chinese people were suffering from CVD, and 1 CVD-related death occurred every 10 seconds. 1 A report revealed that CVD imposed a huge economic, social, and medical burden on patients and their families as well as on the whole society in China in 2013. 2 Health policies need to be implemented to tackle the challenges faced by health-care systems.
Cardiovascular disease is a clinical manifestation of atherosclerosis, a potential life-threatening condition. Thus, understanding the cause of atherosclerosis may contribute to effective treatment and prevention. Atherosclerosis is an inflammatory condition. 3, 4 More importantly, an inflammatory response is present during the whole pathological process of atherosclerosis, including plaque formation, development, and rupture, 3, 5 which ultimately leads to acute stroke, myocardial infarction (MI), and other complications. 6 Several inflammatory factors are involved in the development of CVD, and elucidating these processes is critical for the understanding of inflammatory responses and disease progression. 7 The levels of various inflammation markers, such as C-reactive protein (CRP), tumor necrosis factor a, and interleukin (IL) 6, are elevated in patients with CVD events. In particular, CRP and IL-6 have been associated with the occurrence of CVD. 8, 9 Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a novel inflammation biomarker of atherogenesis used for cardiovascular risk assessment as there is evidence of a link between inflammation and changes in Lp-PLA2 levels. 10 Several epidemiological studies reported that higher Lp-PLA2 level is a marker for the risk of occurrence of CVD events that is independent of the widely recognized cardiovascular risk factors (eg, body mass index (BMI), blood pressure, infections, diabetes, and other systemic factors), [11] [12] [13] [14] although not all studies are in agreement.
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Imaging data reports suggested that the elevated levels of Lp-PLA2 are related to the initiation and promotion of atherosclerosis. 15 The largest meta-analysis, which included 32 prospective studies based mainly on Caucasian populations, revealed that higher Lp-PLA2 levels were associated with Coronary heart disease (CHD), ischemic stroke, and CVD death after adjustment of conventional risk factors; the hazard ratios (HRs; 95% confidence interval [CI]) were 1.11 (1.07-1.16), 1.14 (1.02-1.27), and 1.13 (1.05-1.22), respectively. 11 A study based on a random sample showed that the Lp-PLA2 activity in Japanese men aged 50 to 79 years was significantly and positively associated with carotid intima-media thickness (P ¼ .013) and plaque formation (P ¼ .008) in the artery independently of traditional risk factors. The relationships with Lp-PLA2 mass were qualitatively similar to those of Lp-PLA2 activity. 16 These data support the hypothesis that Lp-PLA2 may play a key role in plaque progression and rupture. Thus, the research on and the understanding of the association between Lp-PLA2 levels and plaque formation might predict atherosclerosis and the occurrence of future CVD events caused by inflammatory reactions.
However, so far, only a few population-based studies specifically addressed the association of Lp-PLA2 level and CVD events (eg, stroke, heart disease, and CVD death) in Chinese older adults. Given this lack of evidence, we evaluated the associations of Lp-PLA2 levels with atherosclerosis and sought to determine whether Lp-PLA2 levels can serve as a predictor of future CVD events in older adults enrolled in the Beijing Longitudinal Study of Aging (BLSA).
Methods

Study Population and Data Collection
We used data obtained from the BLSA, a representative cohort of community-dwelling older adults. As described elsewhere, [17] [18] [19] the cohort was assembled in 1992 and followed up every 2 to 3 years. The present study is based on the data of the 2009 survey, in which 2468 people aged 55 years and older in the selected communities or villages were enrolled and received a questionnaire in each survey. All participants who completed the survey after the beginning of the research project were followed up until the end of 2014. Baseline information on demographic and socioeconomic characteristics, lifestyle, health status, medical history, cognitive status, and current psychological and physical health was obtained from a standardized questionnaire administered through face-to-face interviews by trained interviewers. Where available, the existence of a disease was verified in the medical records provided by the patients. All participants were required to undergo extensive physical examinations and blood tests. Of the total of 2468 participants, 1047 refused to undergo physical examinations and blood tests. In addition, we excluded 164 participants with a history of stroke or MI. Thus, a total of 1257 participants were finally included who were eligible for analysis.
The study was approved by the ethics committee of Xuanwu Hospital, Capital Medical University, Beijing, China. Written informed consent was obtained from all participants.
Physical Examination and Laboratory Testing
Seated blood pressure was measured on the right arm using a standard mercury sphygmomanometer after a minimum of 5-minute rest; the measurements were repeated twice and their mean was used for analysis. Height and body weight were also measured.
All fasting blood samples were drawn in the morning, centrifuged to serum, stored in a refrigerator at a temperature within the range from 2 C to 8 C, and transferred to a central laboratory (IPE Center for Clinical Laboratory, Beijing, China). All biochemical analyses were performed using a Hitachi 7600 automatic analyzer (Hitachi High-Technologies Corporation, Tokyo, Japan). Fasting glucose was determined by the glucose oxidase-peroxidase method. The levels of highdensity lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C) were measured by the direct assay method. Total cholesterol (TC), triglyceride (TG), and creatinine concentrations were measured by a standard enzymatic method. The level of serum Lp-PLA2 was determined using a commercially available enzyme-linked immunosorbent assay kit (Tianjin Kangerke Bioscience, Tianjin, China).
Definition
Based on the Joint National Committee guidelines (JNC VII), 20 hypertension was defined as mean systolic blood pressure of at least 140 mm Hg and/or mean diastolic blood pressure of at least 90 mm Hg and/or having a history of hypertension or use of antihypertensive medication.
The diagnosis of diabetes mellitus was made following the American Diabetes Association criteria: fasting blood glucose (FBG) 7.0 mmol/L or having a history of diabetes or taking a hypoglycemic medication. 21 According to the Adult Treatment Panel III guidelines, 22 patients who had high serum levels of TC (6.21 mmol/L) or TGs (2.26 mmol/L) or were taking a lipid-lowering medication were diagnosed as dyslipidemic.
If the Lp-PLA2 level was >175 ng/mL, it was considered as related to an increased risk of CVD in the Chinese population. 22 Accordingly, serum Lp-PLA2 level was evaluated in 3 categories: Lp-PLA2 < 175, 175 Lp-PLA2 < 223, and Lp-PLA2 223 ng/mL, which was consistent with the criteria used in previous studies. 23, 24 Data on smoking status were collected by self-reporting. The category of smokers included people who reported smoking either at the time of the study or had smoked in the past. Nonsmokers were those respondents who claimed to have never smoked.
Carotid Ultrasonography
All carotid atherosclerotic examinations were performed with a high-resolution (8.0 MHz) color Doppler ultrasound (Logic E; GE Healthcare, Milwaukee, Wisconsin, USA) system according to the guidelines established by the European Stroke Conference. 25 As described elsewhere, 18, 19 common carotid artery intima-media thickening (CCA-IMT) was measured on the far wall of the left and the right CCA (1.0-1.5 cm proximal to the dilatation of the carotid bulb but at least 5 mm below its end). Carotid artery intima-media thickening was defined as the distance between the lumen-intima interface and the mediaadventitia interface free of plaque in the common and internal carotid arteries. 25, 26 The measurements were repeated 3 times, and the results were averaged. Increased CCA-IMT was defined as a mean CCA-IMT value 1.0 mm.
Plaque was defined as a focal structure 50% thicker than the surrounding wall or with a thickness >1.5 mm measured from the intima-lumen interface to the media-adventitia interface. 25 Plaque was classified as unilateral or bilateral, regular or irregular, and heterogeneous or homogeneous. When height variations along the contour of the lesion were between 0.4 and 2 mm, plaques were considered irregular. 27 Heterogeneous plaques were composed of a mixture of hypoechoic, isoechoic, and hyperechoic lesions, whereas homogeneous plaques consisted of only one of these 3 types of plaques. 28 Stenosis of the common or internal carotid artery was examined according to the guidelines of the Society of Radiologists in Ultrasound Consensus Conference. 29 In this study, we identified CCA-IMT thickening and carotid plaque presence as early or accelerated progression of carotid atherosclerosis and carotid stenosis as a severe atherosclerotic progression. Standard operational procedures were used for quality control throughout the process. Two sonographers randomly conducted repeated ultrasonographic examinations for 15% of the participants to assess intra-and inter-reader variability. The average intraclass correlation coefficient for interobserver reliability was 0.97 (95% CI: 0.96-0.98; P < .001). Furthermore, the intraobserver test-retest reliability testing revealed an intraclass correlation coefficient of 0.93 (95% CI: 0.91-0.94; P < .001).
Statistical Analysis
Sample characteristics were described using means and standard deviations for continuous data and percentages for categorical data; the differences were tested using analysis of variance and w 2 test, respectively. To estimate the risk of carotid atherosclerosis, multivariate logistic regression analysis was performed to assess the likelihood of the level of Lp-PLA2 and 95% CIs, adjusted for age, gender, smoking, uric acid, diabetes, pulse pressure, and systolic blood pressure. The values of Akaike information criterion (AIC) and Bayesian information criterion (BIC) were calculated to compare the goodness of fit for each of the models. To evaluate the effect of baseline Lp-PLA2 level on 5-year cardiovascular events or mortality, Cox proportional hazards models were applied after adjustment for the confounding covariates. Cox proportional survival probability curves were assessed separately for each Lp-PLA2 level. A 2-sided P < .05 was considered significant. Data analysis was performed using SPSS version 22.0.
Results
Characteristics of the Study Population
The current study population consisted of 43.8% men with a mean age of 69.3 + 8.1 years ( Table 1 ).The mean (standard deviation [SD]) Lp-PLA2 level was 173.1 (59.1) ng/mL, and statistical significance between the 3 groups was achieved. High-sensitivity C-reactive protein (hsCRP) and FBG levels were significantly more elevated in the group with the highest Lp-PLA2 level (P < .05). Participants with an Lp-PLA2 level 223 ng/mL were slightly older, 70.8 (8.5) versus 69.1 (8.0), P ¼ .01. Lipoprotein-associated phospholipase A2 level was positively correlated with the levels of TC (r ¼ .19; P ¼0.037) and LDL-C (r ¼ .26; P ¼ .010). However, no significant differences were found across other risk factors (eg, gender, BMI, TC, TG, LDL-C, HDL-C, smoking, and drinking) or the presence of diseases (eg, obesity, HT, DM, and dyslipidemia) among the 3 groups.
Carotid Atherosclerosis in Groups With Different Lp-PLA2 Levels
As presented in Table 2 , CCA-IMT thickening and the presence of carotid plaque were more pronounced, demonstrating an increasing trend with the elevation of the Lp-PLA2 level (trend P < .05). However, no such trend was identified in the prevalence of carotid artery stenosis. Furthermore, we did not observe significant differences among the 3 groups in the localization, surface morphology, and echogenicity of plaques.
Association Between Lp-PLA2 Level and Carotid Atherosclerosis
As can be seen in Table 3 , when Lp-PLA2 levels were divided into 3 groups, the multivariate logistic regression analysis showed that the highest Lp-PLA2 level as compared with that in the normal group was strongly associated with CCA-IMT thickening (OR ¼ 1.52, 95% CI: 1.09-2.10) and the presence of carotid plaque (OR ¼ 1.36, 95% CI: 1.04-1.88, model 2; Table 3 ). After adjustment for all potential confounders, the OR increased to 1.60 (95% CI: 1.14-2.26) and 1.42 (95% CI: 1.04-1.99), respectively (model 3, Table 3 ). Meanwhile, the values of the information criteria (AIC and BIC) were significantly reduced (P < .001), which indicated that the addition of all confounders into model 3 substantially improved the model fit (data not shown). Moreover, when using the Lp-PLA2 level Table 3 ). However, the moderately elevated Lp-PLA2 level was not significantly associated with the risk of CCA-IMT thickening and presence of carotid plaque. In addition, no significant associations were found between the increased Lp-PLA2 level (both as a categorical or continuous variable) and the presence of carotid stenosis in these models.
Effect of Lp-PLA2 on CVD Events and Mortality
It is noteworthy that during a median follow-up of 5 years, CVD events occurred in 225 (17.9%) of the 1257 participants, including 113 (8.9%) cases of stroke, 50 (3.9%) of MI, 62 (4.9%) of CVD death, and 155 (12.3%) of death from any cause. In the multivariable cox regression analysis (Table 4) , the highest level of Lp-PLA2, as compared to that of the normal level group, was associated with the risk of MI and the CVD survival after adjustment for age, gender, smoking, uric acid, diabetes, pulse pressure, systolic blood pressure, hsCRP, dyslipidemia, CCA-IMT, and carotid plaque presence. The HRs for MI and CVD death in the participants with the highest Lp-PLA2 level were 1.90-fold (95% CI: 1.09-3.55) and 1.78-fold (95% CI: 1.08-3.13) higher than those of the control group. On the other hand, there were no statistically significant differences when the Lp-PLA2 level was only moderately elevated. Additionally, the elevated Lp-PLA2 level was not associated with an increased risk of stroke and total death, and the HRs for stroke and overall death in patients with elevated Lp-PLA2 Likewise, the survival curve showed that the participants with the highest Lp-PLA2 level were more frequently affected by the occurrence of MI and CVD death (Figure 1 ), although the difference appeared to be less profound when the Lp-PLA2 level was only moderately higher than the control group. However, no difference was observed between the group with the elevated Lp-PLA2 level and the control group concerning the risk of stroke and total death.
In the subgroup analyses, we found that the strength of the associations between Lp-PLA2 levels and CCA-IMT thickening and presence of carotid plaque was stronger in individuals with LDL-C levels 3.0 mmol/L than those with <3.0 mmol/L (Table 5) . Similarly, the risk of MI and CVD death seemed to be higher in individuals with LDL-C levels 3.0 mmol/L than in the ones with levels of <3.0 mmol/L (Table 6 ).
Discussion
The data obtained demonstrate that Lp-PLA2 is associated with CCA-IMT and carotid plaque formation; this association occurred independently of the impact of multiple traditional risk factors. Our findings are consistent with those obtained in previous population-or patient-based studies, 30, 31 whereas others have shown contradictory results. 32, 33 The reasons for these discrepancies could include different study designs (eg, cross-sectional or cohort studies), study populations, sample sizes, effects of potential confounders, and the lack of statistical power. Nevertheless, it is important to note that, consistently with the findings of the current investigation, a recent genetic study did show that a missense mutation in plasma platelet-activating factor (PAF) acetylhydrolase was associated with the development of atherosclerosis in elderly patients. 34 However, we did not observe any significant association between the Lp-PLA2 level and carotid stenosis, which was consistent with the results of previous studies. 33 Therefore, it is Figure 1 . Cox cumulative survival probabilities for people with various Lp-PLA2 levels, adjusted for age, gender, smoking, uric acid, hsCRP, diabetes, pulse pressure, hypertension, dyslipidemia, common carotid artery intima-media thickness, and carotid plaque. The Lp-PLA2 level was as follows: Lp-PLA2 < 175, 175 Lp-PLA2 < 223, and Lp-PLA2 223 ng/mL. CVD indicates cardiovascular disease; hsCRP: high-sensitivity C-reactive protein; Lp-PLA2, lipoprotein-associated phospholipase A2.
reasonable to speculate that Lp-PLA2 might be a partial risk factor only for the early stages of atherosclerosis. Additionally, the smaller sample size of cases with carotid stenosis might have been a potential reason for our negative finding. Future studies are warranted to further elucidate the association between the level of Lp-PLA2 and carotid stenosis. In recent years, Lp-PLA2 has been found to be a vascularspecific inflammatory enzyme that is associated with the development of atherosclerosis and is primarily produced by macrophages, lymphocytes, and foam cells in atherosclerotic plaques. 10, 35 Lipoprotein-associated phospholipase A2 is mostly bound to LDL and is transported to the vulnerable area of the vascular wall to produce pro-inflammatory substances, including oxidized phospholipids and PAF. Lipoproteinassociated phospholipase A2 hydrolyzes oxidized phospholipids in LDL particles within the arterial intima, generating 2 highly inflammatory mediators (ie, lysophosphatidylcholine and oxidized fatty acids) that enhance the proteoglycan synthesis and mitogenic activity of vascular smooth muscle cells. 35 However, this activity is potentially implicated in plaque progression and instability. 5, 36 Moreover, Lp-PLA2 is highly expressed in vulnerable atherosclerotic plaques and allows differentiation between morphologically identical stable and unstable plaques. 37 These data support the hypothesis that Lp-PLA2 appears to be a causal mediator of atherosclerosis.
Notably, we found that Lp-PLA2 level was positively correlated with LDL-C and TC levels, although these associations were generally weak (r < .50). Circulating Lp-PLA2 is located mainly on the LDL-C molecule. In individuals with higher Lp-PLA2 levels, increased hydrolysis of atherogenic small, dense LDL-C likely leads to increased vascular inflammation. Those with low LDL-C but high levels of Lp-PLA2 may therefore be at an increased risk of CVD, which is consistent with results of previous studies. 38, 39 In our analysis, we also demonstrated that the highest level of Lp-PLA2 was an independent predictor of MI and CVD death even after adjustment for conventional risk markers and carotid atherosclerosis status. However, we failed to find a significant association of Lp-PLA2 with the risks of overall stroke and total mortality in multivariable-adjusted models. Our findings are consistent with the results regarding the levels of Lp-PLA2 in older adults in the Rancho Bernardo Study and the Cardiovascular Health Study. 12, 40 In contrast to our negative findings, the Lp-PLA2 level was associated with a risk of stroke in middle-aged adults in the Atherosclerosis Risk in Communities (ARIC) study and among non-Hispanic white older adults in the Northern Manhattan Study. 31, 41 The discrepancies in the associations of Lp-PLA2 with stroke between our study and the ARIC studies could be due to chance or differences in population characteristics, such as age, race-ethnic differences, and varying criteria for selection of study participants. Findings on the differences in risk prediction among different ethnic groups have been published. 31 In particular, Lp-PLA2 levels were associated with the risk of atherosclerotic stroke in non-Hispanic white participants, but not in other race-ethnic groups in the cohort. 31 However, data on the association between Lp-PLA2 levels and ischemic stroke subtypes are unavailable due to the absence of distinction of stroke subtypes in the current study. Further studies are needed to confirm these differences in ischemic stroke subtypes and the reasons for them.
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy (STABILITY) trial and the Stabilization of Plaques using Darapladib (SOLID-TIMI 52) clinical trial evidenced that darapladib decreased plasma Lp-PLA2 activity in patients with stable CHD but did not reduce the occurrence of adverse cardiovascular events and death. 42, 43 Although the results of the current study show a significant positive association between Lp-PLA2 level and coronary events, no benefit of the reduction of Lp-PLA2 activity was seen in these phase 3 trials. 42, 43 The possible reason for the differences might have been the shorter follow-up in the clinical trials compared with the epidemiological studies. Furthermore, it should be noted that the participants in our current study were free of cardiovascular events at baseline, whereas those in the STA-BILITY and SOLID-TIMI 52 trials had stable CHD or acute coronary events, respectively. However, more studies are needed on the effects of genetic variations, the time window, racial differences, the absence or presence of cardiovascular risk factors (eg, hypertension), and the impacts of diverse treatment options. In addition, it will be crucial to adequately evaluate the range of patients who will be most likely to benefit.
To the best of our knowledge, this is the only study to examine the association between the Lp-PLA2 level and carotid atherosclerosis in all phenotypes of Chinese older adults. The strengths of the current investigation include the use of a well-representative population-based sample from a prospective epidemiologic study and the utilization of a standardized assessment of risk factors. However, several potential limitations should be mentioned. First, only the mass, not the activity, of the enzyme was measured; however, it is not clear from previous studies whether Lp-PLA2 mass or activity would be a better marker for potential clinical use. Nevertheless, in many earlier publications, qualitatively similar effects have been exerted by the mass or levels of Lp-PLA2 activity. 11, 31, 35 This question may be elucidated by the ongoing Lp-PLA2 studies collaboration. Second, it could be argued that baseline laboratory and ultrasonic data from all participants in our cohort were not available for analysis, which might have biased our results and conclusions. However, we compared the characteristics of an entire cohort and the samples analyzed in this study, and no significant difference was found, except that those who did not allow conducting such measurements tended to be older (data not shown). Thus, our results seem to slightly underestimate the association between the level of Lp-PLA2 and carotid atherosclerosis. Third, in the adjusted analyses, however, the effects of substantial residual confounding might have remained because lipids and other risk factors might have been biased and because detailed information concerning some potential confounding factors (eg, medication for CVD or stroke) was unavailable for analysis in the current study. Finally, we used baseline characteristics to evaluate Lp-PLA2 level and several other covariates, even though such variables can change over time. For future work, more detailed time-series analyses with multiple survey data can facilitate the assessment of the relationships between the outcome and the dynamic changes.
In summary, herein, we report that an elevated Lp-PLA2 level (223 ng/mL) was associated with an increased risk of atherosclerosis in older adults in a population-based prospective study. In addition, we have shown that Lp-PLA2 may be a valuable predictor of MI and CVD death independently of several established risk factors and the presence of carotid atherosclerosis. Despite the promising results of some studies, there are still inconsistencies in the findings regarding the potential use of Lp-PLA2, especially in clinical settings. Further studies, focused on the issues investigated here (ie, genetic variations and time-window effect), should be performed to clarify the exact role of Lp-PLA2 in carotid atherosclerosis and cardiovascular outcomes.
